Comparative Pharmacology
Head-to-head clinical analysis: QUETIAPINE FUMARATE versus RISVAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUETIAPINE FUMARATE versus RISVAN.
QUETIAPINE FUMARATE vs RISVAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonist at serotonin 5-HT2A, dopamine D2, histamine H1, alpha1-adrenergic, and muscarinic M1 receptors. Also partial agonist at serotonin 5-HT1A and dopamine D2 receptors (depending on dose).
Risperidone is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and H1 histaminergic receptors.
Immediate release: 25-100 mg orally twice daily, titrated as needed up to 400-800 mg/day divided twice daily. Extended release: 50-200 mg orally once daily, titrated up to 400-800 mg/day once daily.
70 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 hours (quetiapine) and 9-12 hours for the active metabolite norquetiapine; with extended-release formulation, effective half-life is ~7 hours due to slower absorption. Clinical steady-state achieved within 2 days.
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 20-30 hours in hepatic impairment (Child-Pugh B/C).
Renal: 73% (20% unchanged, remainder as metabolites); Fecal: 21%; Approximately 5% excreted in feces as unchanged drug.
Renal: 30% unchanged; Fecal: 65% (biliary excretion of metabolites); 5% other.
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic